Abstract
Oxcarbazepine (OXC) has attracted much attention owing to its multiple health benefits. OXC is an anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy. This study developed and validated a simple, specific, sensitive and reliable stability indicating UV-Spectrophotometric method for the quantitative determination of oxcrbazepine in pure and in pharmaceutical dosage forms. Analysis was performed using methanol: aceonitrile (50:50) as diluents. UV detection was performed at 254 nm. The calibration plot was linear over a concentration range of 0.0-15 μg ml-1 with correlation coefficient values >0.9986. The method was validated for specificity, linearity, precision, accuracy, limit of detection, limit of quantification and robustness. The forced degradation studies were performed by using HCl, NaOH, H2O2, thermal and UV radiation. Oxcarbazepine is more sensitive towards alkaline conditions and very much resistant towards acidic, oxidative and photolytic degradations. The method was validated as per ICH guidelines. The RSD for intra- and inter-day precision were found to be lesser than 3%. The percentage recovery was in good agreement with the labeled amount in the pharmaceutical formulations and the method is simple, specific, precise and accurate for the determination of oxcarbazepine in pharmaceutical formulations
Highlights
UV-Vis Spectrophotometer (UV) is long-used analytical equipment with property of high sensitivity and selectivity
The photolytic degradation was not observed when OXC was exposed in solid state to UV light for 3 days
Major degradation up to 15.73% occurred under alkaline conditions
Summary
UV-Vis Spectrophotometer (UV) is long-used analytical equipment with property of high sensitivity and selectivity. OXC, is a keto analog of carbamazepine and is an anticonvulsant and mood stabilizing drug. OXC is known to exert antiepileptic activity by blockade of voltage–dependent sodium channels in the brain. It protects mice and rats against generalized tonic-clonic seizures induced by electroshock which is thought to act via inhibition of sodium channel activity. It is commercially available under trade names, Oxrate (Wockhard), Oxetol (Sun Pharma), Oxcarb (Cipla) etc. The drug is not yet official in any pharmacopoeias
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
